CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Amikacin Sulfate

硫酸阿米卡星 杂质对照品Amikacin Sulfate Impurities

10 个杂质条目10 impurity entries

本页汇总 硫酸阿米卡星 的 10 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 10 impurity reference standards of Amikacin Sulfate. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 硫酸阿米卡星(Amikacin Sulfate)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsA novel high throughput 96-well-based fluorimetric method to measure amikacin in pharmaceutical formulations: development using response surface methodology
    Luminescence : the journal of biological and chemical luminescence · 2022 · Maxwell A et al.  ·  PMID 35322527  ·  DOI
  2. 分析方法Analytical MethodsDevelopment and validation of a novel LC non-derivatization method for the determination of amikacin in pharmaceuticals based on evaporative light scattering detection
    Journal of pharmaceutical and biomedical analysis · 2006 · Galanakis EG et al.  ·  PMID 16242884  ·  DOI
  3. 分析方法Analytical MethodsComparison of two tourniquets and determination of amikacin sulfate concentrations after metacarpophalangeal joint lavage performed simultaneously with intravenous regional limb perfusion in horses
    American journal of veterinary research · 2011 · Alkabes SB et al.  ·  PMID 21529212  ·  DOI
  4. 分析方法Analytical MethodsReagent-free determination of amikacin content in amikacin sulfate injections by FTIR derivative spectroscopy in a continuous flow system
    Journal of pharmaceutical analysis · 2014 · Ovalles JF et al.  ·  PMID 29403874  ·  DOI
  5. 分析方法Analytical MethodsA novel luminol-based chemiluminescence method for the determination of amikacin sulfate in serum by using trivalent copper-periodate complex
    Journal of pharmaceutical analysis · 2013 · Hu YF et al.  ·  PMID 29403840  ·  DOI

硫酸阿米卡星 —— 原料药与杂质对照品Amikacin Sulfate — drug substance & impurities

共 10 个条目(含原料药本体)10 items incl. the drug substance
Amikacin Disulfate structure
—
二硫酸阿米卡星Amikacin Disulfate
Amikacin Disulfate
CAS No.39831-55-5
Chemical FormulaC22H43N5O13·2(H2O4S)
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 11 structure
11
硫酸阿米卡星杂质11Amikacin Impurity 11
Amikacin Impurity 11
CAS No.103119-91-1
Chemical FormulaC6H13NO5
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 11 Hydrochloride structure
11
硫酸阿米卡星杂质11 盐酸盐Amikacin Impurity 11 Hydrochloride
Amikacin Impurity 11 Hydrochloride
CAS No.84064-35-7
Chemical FormulaC6H13NO5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 14 structure
14
硫酸阿米卡星杂质14Amikacin Impurity 14
Amikacin Impurity 14
CAS No.207305-60-0
Chemical FormulaC9H17NO5
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 18 structure
18
硫酸阿米卡星杂质18Amikacin Impurity 18
Amikacin Impurity 18
CAS No.197909-66-3
Chemical FormulaC26H50N6O15
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 20 structure
20
硫酸阿米卡星杂质20Amikacin Impurity 20
Amikacin Impurity 20
CAS No.1793053-94-7
Chemical FormulaC22H42N4O14
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 25 structure
25
硫酸阿米卡星杂质25Amikacin Impurity 25
Amikacin Impurity 25
CAS No.34291-03-7
Chemical FormulaC21H41N5O12
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 26 structure
26
硫酸阿米卡星杂质26Amikacin Impurity 26
Amikacin Impurity 26
CAS No.34291-02-6
Chemical FormulaC21H41N5O12
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 27 Hydrochloride structure
27
硫酸阿米卡星杂质27 盐酸盐Amikacin Impurity 27 Hydrochloride
Amikacin Impurity 27 Hydrochloride
CAS No.4460-60-0
Chemical FormulaC6H13NO5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 27 structure
27
硫酸阿米卡星杂质27Amikacin Impurity 27
Amikacin Impurity 27
CAS No.802551-71-9
Chemical FormulaC6H13NO5
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

For formulation & analytical R&D

硫酸阿米卡星 杂质谱研究要点Amikacin Sulfate — impurity profiling notes

下面这些是拿到 硫酸阿米卡星 的 10 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 10 impurity entries for Amikacin Sulfate, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances